IRWDNasdaqPharmaceutical PreparationsFiscal year ends December 31
IRONWOOD PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.56+0.06 (+1.71%)
Close on Oct 19, 2026
- Market cap
- $595.16M
- P/E (TTM)
- 4.6
- Dividend yield
- –
Ironwood Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Ironwood Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $588.25M | $164.85M |
| Enterprise Value | $509.13M | $87.06M |
| PE Ratio | 4.62 | 19.63 |
| PS Ratio | 1.51 | 3.60 |
| P/OCF Ratio | 3.17 | 13.32 |
Enterprise value
| Measure | Ironwood Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 1.31 | 2.43 |
| EV / EBITDA | 2.17 | 14.69 |
| EV / EBIT | 2.17 | 18.47 |
Income (trailing twelve months)
| Measure | Ironwood Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $389.32M | $57.94M |
| Operating Income | $234.17M | -$21.44M |
| Pretax Income | $207.38M | -$14.45M |
| Net Income | $129.87M | -$22.46M |
| EBITDA | $234.17M | -$16.91M |
| EPS (Diluted) | $0.77 | -$0.83 |
Margins
| Measure | Ironwood Pharmaceuticals | Industry median |
|---|---|---|
| Operating Margin | 60.1% | -44.5% |
| Pretax Margin | 53.3% | -13.0% |
| Profit Margin | 33.4% | -39.2% |
| EBITDA Margin | 60.1% | -31.3% |
Returns
| Measure | Ironwood Pharmaceuticals | Industry median |
|---|---|---|
| Return on Assets (ROA) | 41.4% | -41.0% |
| Return on Capital Employed (ROCE) | 92.8% | -37.8% |
Growth
| Measure | Ironwood Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 26.2% | 6.01% |
| Revenue Growth (3Y CAGR) | -10.3% | 2.25% |
| Revenue Growth (5Y CAGR) | -5.33% | 6.42% |
| EPS Growth (3Y CAGR) | -46.1% | -0.17% |
| EPS Growth (5Y CAGR) | -25.6% | 3.77% |
Balance sheet
| Measure | Ironwood Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $79.13M | $62.42M |
| Net Cash (Debt) | $79.13M | $15.68M |
| Net Cash Per Share | $0.48 | $0.66 |
| Equity (Book Value) | -$161.84M | $48.79M |
| Book Value Per Share | -$0.98 | $1.36 |
| Tangible Book Value | -$163.48M | $23.06M |
| Working Capital | $166.35M | $75.77M |
Financial position
| Measure | Ironwood Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 6.06 | 3.30 |
| Quick Ratio | 5.84 | 2.39 |
| Interest Coverage | 7.17 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Ironwood Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | $185.56M | -$12.35M |
Efficiency
| Measure | Ironwood Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 1.24 | 0.38 |
| Revenue Per Employee | $3.89M | $398.96K |
| Profits Per Employee | $1.30M | -$703.34K |
| Employee Count | 100 | 74 |
Dividends and yields
| Measure | Ironwood Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | 22.1% | -22.7% |
Shares
| Measure | Ironwood Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 165,240,000 | 58,179,650 |
| Shares Change (YoY) | -4.46% | 11.1% |
| Shares Change (QoQ) | 0.38% | 0.54% |
| Float | 138,739,000 | 49,173,100 |
| Shares Held by Insiders | 16.0% | 11.6% |
| Shares Held by Institutions | 97.2% | 59.4% |
Taxes
| Measure | Ironwood Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | $77.51M | $91.50K |
| Effective Tax Rate | 37.4% | 20.6% |
Scores
| Measure | Ironwood Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -2.20 | -0.24 |
| Piotroski F-Score | 6 | 4 |
Calculated by StockData from Ironwood Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.